From: Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment
Mean ± SD
Range
Time on treatment (months)
23.1 ± 24.7
0.0–76.0
Time on MAA (months)
7.1 ± 4.6
0.0–12.0
Age (months)
106.5 ± 54.6
50.0–224.0
Distance travelled by families (km)a
209.5 ± 110.6
6.5–398.0